Drugs / Hemay181
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07446816 | Dec 2025 → Aug 2026 overdue | cancer | Ganzhou Hemay Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05749432 | Mar 2023 → Jan 2026 overdue | cancer | Ganzhou Hemay Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemay181 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05749432 ↗ |
| Route | Intravenous | “Hemay181 will be given intravenously” NCT05749432 ↗ |